[1]张静,张蓉.替加环素对患者凝血指标影响的临床研究[J].第三军医大学学报,2019,41(15):1485-1490.
 ZHANG Jing,ZHANG Rong.Effect of tigecycline on coagulation markers: a retrospective study[J].J Third Mil Med Univ,2019,41(15):1485-1490.
点击复制

替加环素对患者凝血指标影响的临床研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第15期
页码:
1485-1490
栏目:
临床医学
出版日期:
2019-08-15

文章信息/Info

Title:
Effect of tigecycline on coagulation markers: a retrospective study
作者:
张静张蓉
陆军军医大学(第三军医大学)第二附属医院药剂科
Author(s):
ZHANG Jing ZHANG Rong

Department of Pharmacy, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China

关键词:
替加环素凝血指标纤维蛋白原高剂量
Keywords:
tigecycline coagulation markers fibrinogen high dose
分类号:
R446.11; R965.3; R978.14
文献标志码:
A
摘要:
目的 分析替加环素对感染患者凝血指标的影响,并筛选出凝血指标异常的危险因素。方法 利用医院信息系统及美康合理用药监测系统筛选出2016年1月至2017年12月入我院治疗,并使用替加环素的病例,观察使用替加环素后是否发生凝血指标异常,并比较用药前后纤维蛋白原(FBG)、凝血酶原时间(PT)、部分激活凝血酶原时间(APTT)、凝血酶时间(TT)、血小板(PLT)、丙氨酸氨基转移酶(ALT),血清总胆红素(TBIL)、肾小球滤过率(eGFR)水平的差异。再根据患者是否发生凝血指标异常,利用二分类Logistic回归筛选替加环素导致凝血指标异常的危险因素。结果共纳入97例合格病例进行分析,其中男性69例(71.1%),女性28例(28.9%);年龄(56.93±19.31)岁。使用替加环素后,患者FBG水平显著降低(P<0.05);PT、APTT、TT明显延长(P<0.05);PLT水平无明显改变。同时患者ALT、TBIL水平用药前后无明显差异;C反应蛋白(CRP)、降钙素原(PCT)用药后较用药前差异有统计学意义(P<0.05),WBC用药前后无统计学差异,总体WBC、CRP、PCT用药后低于用药前,患者感染状态较用药前改善;eGFR值用药前后差异有统计学意义(P<0.05),用药后患者肾功能好转。Logistic分析发现,高剂量使用替加环素是发生凝血指标异常的危险因素(P<0.05,OR=3.96)。结论 替加环素可引起FBG下降,PT、APTT、TT延长,且高剂量使用的患者更易发生该不良事件。
 
Abstract:

Objective To determine the effect of tigecyclin on coagulation markers in the patients taking it, and screen out the related risk factors. MethodsA retrospective study was carried out on the patients with tigecycline treatment admitted to our hospital from January 2016 to December 2017 based on our hospital information system and the Meikang rational drug use monitoring system. Fibrinogen (FBG) level, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), platelet (PLT) count, glomerular filtration rate (eGFR), and levels of alanine aminotransferase (ALT) and serum total bilirubin (TBIL) were compared before and after tigecycline administration. Finally, according to whether patients had abnormal coagulation indicators, Logistic regression was used to screen out high-risk factors of abnormal coagulation indexes caused by tigecycline. ResultsA total of 97 qualified cases were included in this study, including 69 males (71.1%) and 28 females (28.9%), at a mean age of 56.93±19.31 years. Tigecycline treatment resulted in significantly decreased FBG level (P<0.05) and prolonged PT, APTT and TT (P<0.05), but no such change was seen in PLT count. At the same time, there were no significant differences in ALT and TBIL levels before and after administration, and CRP and PCT showed significant differences (P<0.05), while WBC count showed no significant difference. The total WBC count, and CRP and PCT levels were decreased after administration, indicating the patients’ infection status was improved. The eGFR value was remarkably improved (P<0.05), indicating better renal function. Logistic analysis showed that high dose of tigecycline was a risk factor for coagulopathy (P<0.05, OR=3.96). ConclusionTigecycline may cause decreased FBG, prolonged PT, APTT and TT, and the patients taking high dose tigecycline are prone to this adverse event.

参考文献/References:

[1]孙桂凤, 陈頔, 孙钊, 等. 新一代抗菌药物替加环素的研究进展[J].药品评价,2014,11(12):21-27. DOI:10.3969/j.issn.1672-2809.2014.12.004.
SUN G F, CHEN D, SUN Z, et al. Progress in the research of tigecycline, a new generation of antibacterials[J]. Drug Eva,2014,11(12):21-27.DOI:10.3969/j.issn.1672-2809.2014.12.004.
[2]耐甲氧西林金黄色葡萄球菌感染防治专家委员会. 耐甲氧西林金黄色葡萄球菌感染防治专家共识2011年更新版[J]. 中华实验和临床感染病杂志(电子版),2011,5(3):66-72.
Expert committee on the prevention and treatment of mrsa infection. Expert consensus on the prevention and treatment of mrsa infection updated in 2011[J]. Chin J Exp Clin Infect Dis(Electr Vers),2011,5(3):66-72.
[3]陈佰义, 何礼贤, 胡必杰, 等. 中国鲍曼不动杆菌感染诊治与防控专家共识[J]. 中华医学杂志, 2012, 92(2): 76-85. DOI:10.3760/cma.j.issn.0376-2491.2012.02.002.
CHEN B Y, HE L X, HU B J, et al. Expert consensus on the diagnosis, treatment, prevention and control of acinetobacter baumannii infection[J]. National Med J China, 2012, 92(2): 76-85. DOI:10.3760/cma.j.issn.0376-2491.2012.02.002.
[4]周华,李光辉,陈佰义,等. 中国产超广谱β-内酰胺酶肠杆菌科细菌感染应对策略专家共识[J]. 中华医学杂志,2014,94(24):1847-1856.DOI:10.3760/cma.J.issn.0376-2491.2014.24.003. 
ZHOU H,LI G H,CHEN B Y,et al. Expert consensus on the strategy for the treatment of infection caused by enterobacteriaceae producing extented—spectrum betalactamases[J]. National Med J China,2014,94(24): 1847-1856.DOI:10.3760/cma.J.issn.0376-2491.2014.24.003.
[5]GIRYES S, AZZAM Z S, ISMAEL-BADARNEH R, et al. Severe coagulation disorder and thrombocytopenia associated with tigecycline-case report and review of literature[J]. Curr Drug Saf, 2017, 12(1): 7-9. DOI:10.2174/157488 6311666160920090714.
[6]PIERINGER H, SCHMEKAL B, BIESENBACH G, et al. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline[J]. Ann Hematol, 2010, 89(10):1063-1064.DOI:10.1007/s00277-010-0911-7.
[7]ROSSITTO G, PIANO S, ROSI S, et al. Life-threatening coagulopathy and hypofibrinogenaemia induced by tigecycline in a patient with advanced liver cirrhosis[J]. Eur J Gastroenterol Hepatol,2014,26(6):681-684. DOI:10.1097/MEG.0000000000000087.
[8]SABANIS N, PASCHOU E, GAVRIILAKI E, et al. Hypofibrinogenemia induced by tigecycline: A potentially life-threatening coagulation disorder[J]. Infect Dis (Lond), 2015, 47(10):743-746.DOI:10.3109/23744235.2015.1043942.
[9]ZHANG Q, ZHOU S M, ZHOU J. Tigecycline treatment causes a decrease in fibrinogen levels[J]. Antimicrob Agents Chemother,2015,59(3):1650-1655.DOI:10.1128/AAC.04305-14.
[10]尚红,王毓三,申子瑜. 全国临床检验操作规程[M]. 4版.北京:人民卫生出版社,2015. 
SHANG H,WANG Y S,SHEN Z Y. National guide to clinical laboratory procedures[M]. 4th Edition. Beijing: People’s Medical Publishing House,2015.
[11]刘春亮, 王华. 替加环素的研究进展及临床应用[J]. 安徽医药, 2007, 11(7): 648-650. DOI:10.3969/j.issn.1009-6469.2007.07.045.
LIU C L, WANG H. Research progress and clinical application of tigecycline[J]. Anhui Med Pharmaceutical J, 2007,11(7):648-650.DOI:10.3969/j.issn.1009-6469.2007.07.045.
[12]程仕虎, 王睿. 新一代四环素类药物替加环素的研究进展[J]. 科学技术与工程, 2007, 7(16): 4123-4130. DOI:10.3969/j.issn.1671-1815.2007.16.033.
CHENG S H, WANG R. Research development of tigecycline: A new glycylcycline antimicrobial agent[J]. Sci Tech Engineering,2007,7(16):4123-4130.DOI:10.3969/j.issn.1671-1815.2007.16.033.
[13]蒋春晖. 替加环素抗耐药菌作用的研究进展[J]. 中国药房, 2012, 23(42): 4013-4015.
JIANG C H. Advances in research on the effects of tigecycline on resistant bacteria[J]. China Pharmacy, 2012, 23(42): 4013-4015.
[14]钟雪, 陈东科, 许宏涛, 等. 替加环素研究新进展[J]. 中国抗生素杂志, 2015, 40(11): 870-875. DOI:10.3969/j.issn.1001-8689.2015.11.015.
ZHONG X, CHEN D K, XU H T, et al. New advance in the study of tigecycline[J]. Chin J Antibiotics, 2015, 40(11): 870-875. DOI:10.3969/j.issn.1001-8689.2015.11.015.
[15]MURALIDHARAN G, MICALIZZI M, SPETH J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects[J]. Antimicrob Agents Chemother, 2005,49(1):220-229.DOI:10.1128/AAC.49.1.220-229.2005.
[16]薛峰. 替加环素对患者凝血功能影响的临床回顾分析[D]. 济南: 山东大学, 2016.
XUE F. Clinical retrospective analysis of tigecycline treatment effect on patients’ coagulation function[D]. Jinan: Shandong University, 2016.
[17]ELLIS-GROSSE E J, BABINCHAK T, DARTOIS N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam[J]. Clin Infect Dis, 2005, 41(Suppl 5): S341-S353. DOI:10.1086/431675.
[18]LEVI M. The coagulant response in sepsis and inflammation[J]. Hamostaseologie, 2010, 30(1): 10-12, 14-6.
[19]肖昌钱, 韩奇. 替加环素致血小板减少2例[J]. 医药导报, 2018, 37(1): 125-127. DOI:10.3870/j.issn.1004-0781.
XIAO C Q, HAN Q. 2 cases of thrombocytopenia caused by tigecycline[J]. Herald Med, 2018, 37(1): 125-127. DOI:10.3870/j.issn.1004-0781.
[20]潘虹, 董亮, 张秀红. 替加环素致1例凝血功能障碍[J]. 药学与临床研究, 2018, 26(3): 233-234. DOI:10.13664/j.cnki.pcr.2018.03.022.
PAN H, DONG L, ZHANG X H. One case of coagulation dysfunction caused by tigecycline[J]. Pharmaceutical Clin Res,2018,26(3):233-234.DOI:10.13664/j.cnki.pcr.2018.03.022.
[21]WU X Q, ZHAO P, DONG L, et al. A case report of patient with severe acute cholangitis with tigecycline treatment causing coagulopathy and hypofibrinogenemia[J]. Med (Baltimore),2017,96(49):e9124.DOI:10.1097/MD.0000000000009124.
[22]WU P C, WU C C. Tigecycline-associated hypofibrinogenemia: A case report and review of the literature[J]. IDCases, 2018, 11: 56-57. DOI:10.1016/j.idcr.2018.01.003.
[23]黄梅娟, 薛加玲, 于维松. 替加环素相关凝血功能障碍文献概述[J]. 中国药师, 2017, 20(11): 2046-2048,2095.
HUANG M J, XUE J L, YU W S. Summary of the literatures on coagulation disorders associated with tigecyclin[J]. China Pharmacist, 2017, 20(11): 2046-2048,2095.
[24]FISH R J, NEERMAN-ARBEZ M. Fibrinogen gene regulation[J]. Thromb Haemost, 2012, 108(3): 419-426. DOI:10.1160/TH12-04-0273.
[25]WANG H J, DENG J, WANG J Y, et al. Serum miR-122 levels are related to coagulation disorders in sepsis patients[J]. Clin Chem Lab Med, 2014, 52(6): 927-933. DOI:10.1515/cclm-2013-0899.
[26]ROUTSI C, KOKKORIS S, DOUKA E, et al. High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections[J]. Int J Antimicrob Agents,2015,45(1):90-93. DOI:10.1016/j.ijantimicag.2014.07.014.
[27]MCMAHAN J, MOENSTER R P. Tigecycline-induced coagulopathy[J]. AJHP, 2017, 74(3): 130-134. doi:10.2146/ajhp150894.
 

更新日期/Last Update: 2019-08-13